M. Dror Michaelson
Impact in
- Pulmonary and Respiratory Medicine top 0.02%
- Renal cell carcinoma treatment
- Prostate Cancer Treatment and Research
- Cancer Research top 0.1%
- Cancer Genomics and Diagnostics
- Cancer, Hypoxia, and Metabolism
Papers in
-
- Renal cell carcinoma treatment 129
- Prostate Cancer Treatment and Research 32
- Oncology 59
- Cancer Immunotherapy and Biomarkers 15
- Cancer Diagnosis and Treatment 12
- Co-authors
- Robert J. Motzer (64 shared papers)Thomas E. Hutson (33 shared papers)Ronald M. Bukowski (26 shared papers)Sindy T. Kim (9 shared papers)Robert A. Figlin (33 shared papers)Charles M. Baum (13 shared papers)Piotr Tomczak (12 shared papers)Sylvie Négrier (12 shared papers)
- Journals
- Journal of Clinical Oncology (83 papers)Annals of Oncology (16 papers)Cancer (8 papers)British Journal of Cancer (8 papers)The Oncologist (7 papers)
- Partner nations
- United StatesCanadaUnited Kingdom
In The Last Decade
M. Dror Michaelson
213 papers receiving 17.4k citations
M. Dror Michaelson's Hit Papers
Peers
Comparison fields: 5 of 128
- Pulmonary and Respiratory Medicine 11.1k
- Cancer Research 4.4k
- Oncology 4.4k
- Molecular Biology 6.8k
- Hepatology 320
Countries citing papers authored by M. Dror Michaelson
This map shows the geographic impact of M. Dror Michaelson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Dror Michaelson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Dror Michaelson more than expected).
Fields of papers citing papers by M. Dror Michaelson
This network shows the impact of papers produced by M. Dror Michaelson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Dror Michaelson. The network helps show where M. Dror Michaelson may publish in the future.
Co-authors
The 25 scholars most cited alongside M. Dror Michaelson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 219 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma Hit paper breakdown → | 2007 | 4636 |
| 2 | Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma Hit paper breakdown → | 2009 | 1773 |
| 3 | Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma Hit paper breakdown → | 2005 | 1360 |
| 4 | Sunitinib in Patients With Metastatic Renal Cell Carcinoma Hit paper breakdown → | 2006 | 1010 |
| 5 | Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial Hit paper breakdown → | 2015 | 716 |
| 6 | Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial Hit paper breakdown → | 2013 | 561 |
| 7 | Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial Hit paper breakdown → | 2017 | 525 |
| 8 | 2007 | 365 | |
| 9 | 2008 | 333 | |
| 10 | Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update Hit paper breakdown → | 2018 | 280 |
| 11 | 2007 | 269 | |
| 12 | Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience Hit paper breakdown → | 2017 | 261 |
| 13 | 2007 | 252 | |
| 14 | 2008 | 175 | |
| 15 | 2007 | 169 | |
| 16 | 2005 | 164 | |
| 17 | 2008 | 148 | |
| 18 | 2007 | 144 | |
| 19 | 2008 | 134 | |
| 20 | 2010 | 127 |
About M. Dror Michaelson
M. Dror Michaelson is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Molecular Biology and Surgery, having authored 219 papers that have together received 17.8k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (129 papers), Cancer Genomics and Diagnostics (39 papers), Prostate Cancer Treatment and Research (32 papers), Renal and related cancers (27 papers), Bladder and Urothelial Cancer Treatments (27 papers), Economic and Financial Impacts of Cancer (18 papers), Cancer Immunotherapy and Biomarkers (15 papers) and Cancer Diagnosis and Treatment (12 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (11.1k citations), Cancer Research (4.4k citations), Oncology (4.4k citations), Molecular Biology (6.8k citations) and Hepatology (320 citations). M. Dror Michaelson has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Robert J. Motzer, Thomas E. Hutson, Ronald M. Bukowski, Sindy T. Kim, Robert A. Figlin, Charles M. Baum, Piotr Tomczak, Sylvie Négrier, Stéphane Oudard and Isan Chen. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer, British Journal of Cancer and The Oncologist.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.